1 / 6

Regulation of Visfatin in Adipocytes Treated with PPARg and GW1929

This study investigates the impact of PPARg and GW1929 on Visfatin expression in adipocytes using various treatments and molecular analyses.

michaeldawson
Download Presentation

Regulation of Visfatin in Adipocytes Treated with PPARg and GW1929

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure 1 D A B C * ** 2.5 4 6 5 Control Control Control Control *** *** * GW1929 GW1929 GW1929 GW1929 *** 5 4 2 RSG * RSG RSG 3 4 * 3 1.5 * Visfatin / cyclophilin mRNA * Visfatin / cyclophilin mRNA Visfatin / cyclophilin mRNA Visfatin / cyclophilin mRNA * ** * 3 2 *** 2 1 2 1 Control Control Control 1 0.5 RSG RSG RSG 1 3H 6H 9H 0 12H 24H AcLDL ATM * * * E F H G 3 7 *** *** *** Control * 4 3 6 GW1929 5 *** *** 3 2 *** Visfatin / cyclophilin mRNA CD36 / cyclophilin mRNA 4 FABP4 / cyclophilin mRNA 2 Visfatin / cyclophilin mRNA 2 3 § 1 1 2 1 1 T00709 AdGFP AdGFP AdGFP Control AdPPARg AdPPARg AdPPARg

  2. A B Figure 2 1.6 3 Control Control GW1929 GW1929 1.4 RSG RSG * 1.2 * 2 1 mVisfatin / cyclophilin mRNA 0.8 mCD36 / cyclophilin mRNA 0.6 1 0.4 0.2 C D 3 1.4 Control Control *** GW1929 GW1929 1.2 2.5 1 2 0.8 CD36 / cyclophilin mRNA Visfatin / cyclophilin mRNA 1.5 0.6 1 0.4 0.5 0.2

  3. A B (DR1-Visfatin PPRE)6 RXRa +PPARg 14 RXRa +PPARg Ab anti-PPARg Control ** Lysate Cold DR1 Visfatin- PPRE wt Cold DR1-Visfatin-PPRE mut PPARg Lysate RXRa 12 GW1929 gal x 1000 gal x 1000 10 8 §§ - - b b 6 RLU / 4 2 pSG5 pSG5-PPARg (DR1-consensus PPRE)6 70 Control ** 60 GW1929 50 §§§ gal x 1000 gal x 1000 40 - - b b 30 RLU / RLU / 20 * 10 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 pSG5 pSG5-PPARg DR1-consensus PPRE DR1-Visfatin-PPRE wt Figure 3

  4. A B ** 2.5 7 Control Control ** *** GW1929 GW1929 6 ** 2 ** ns ** 5 *** * 1.5 §§ § Visfatin / cyclophilin mRNA 4 Visfatin / cyclophilin mRNA §§ 3 * 1 * 2 0.5 1 M2 RM IL-1b LPS TNFa RM Figure 4

  5. GW1929 Control Visfatin A B b-actin 2.5 1.6 *** * 1.4 2 1.2 1.0 1.5 Visfatin secretion (ng/mL) Visfatin / b-actin 0.8 1 0.6 0.4 0.5 0.2 Control GW1929 Control GW1929 Figure 5

  6. Figure 6 § * * B C A § * 140 * 140 140 Control Control Control * * * * GW1929 GW1929 GW1929 130 120 120 RSG * * 120 100 100 * 110 80 80 * * Intracellular NAD+ concentration (%) Intracellular NAD+ concentration (%) Intracellular NAD+ concentration (%) §§ § 100 60 60 90 40 40 80 20 20 scrambled siRNA visfatin AdPPARg vehicle AdGFP FK866

More Related